Reference growth curves to identify weight status (underweight, overweight or obesity) in children and adolescents: systematic review

Alves, Carlos Alencar Souza; Martins, Priscila Custódio; Moreno, Luís A.; Silva, Diego Augusto Santos

doi:10.1017/s0007114522003786

Cited by 4 publications

(1 citation statement)

References 91 publications

(557 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These children are called large for gestational age (LGA) when they have a generalized overgrowth ( Manor and Lalani, 2020 ). Anthropometric postnatal indicators usually used for reference growth curves are height and weight for age, body mass index (BMI), and head circumference ( Alves Junior et al, 2023 ).…”

Section: Introductionmentioning

confidence: 99%

Molecular mechanisms of human overgrowth and use of omics in its diagnostics: chances and challenges

Prawitt,

Eggermann

2024

Front. Genet.

View full text Add to dashboard Cite

Overgrowth disorders comprise a group of entities with a variable phenotypic spectrum ranging from tall stature to isolated or lateralized overgrowth of body parts and or organs. Depending on the underlying physiological pathway affected by pathogenic genetic alterations, overgrowth syndromes are associated with a broad spectrum of neoplasia predisposition, (cardio) vascular and neurodevelopmental anomalies, and dysmorphisms. Pathologic overgrowth may be of prenatal or postnatal onset. It either results from an increased number of cells (intrinsic cellular hyperplasia), hypertrophy of the normal number of cells, an increase in interstitial spaces, or from a combination of all of these. The underlying molecular causes comprise a growing number of genetic alterations affecting skeletal growth and Growth-relevant signaling cascades as major effectors, and they can affect the whole body or parts of it (mosaicism). Furthermore, epigenetic modifications play a critical role in the manifestation of some overgrowth diseases. The diagnosis of overgrowth syndromes as the prerequisite of a personalized clinical management can be challenging, due to their clinical and molecular heterogeneity. Physicians should consider molecular genetic testing as a first diagnostic step in overgrowth syndromes. In particular, the urgent need for a precise diagnosis in tumor predisposition syndromes has to be taken into account as the basis for an early monitoring and therapy. With the (future) implementation of next-generation sequencing approaches and further omic technologies, clinical diagnoses can not only be verified, but they also confirm the clinical and molecular spectrum of overgrowth disorders, including unexpected findings and identification of atypical cases. However, the limitations of the applied assays have to be considered, for each of the disorders of interest, the spectrum of possible types of genomic variants has to be considered as they might require different methodological strategies. Additionally, the integration of artificial intelligence (AI) in diagnostic workflows significantly contribute to the phenotype-driven selection and interpretation of molecular and physiological data.

show abstract

Section: Introductionmentioning

confidence: 99%

Molecular mechanisms of human overgrowth and use of omics in its diagnostics: chances and challenges

Prawitt,

Eggermann

2024

Front. Genet.

View full text Add to dashboard Cite

show abstract

Treatment with brivaracetam has no apparent long‐term effects on body weight in pediatric patients with epilepsy

Floricel,

Reichel,

Dickson

et al. 2024

Epilepsia Open

View full text Add to dashboard Cite

ObjectiveThe objective of this study is to evaluate possible long‐term effects of treatment with brivaracetam (BRV) on body weight in children with epilepsy.MethodPost hoc analysis of data from patients (aged 1 month to <17 years) with ≥6 months of BRV treatment in a long‐term, open‐label trial (N01266 [NCT01364597]). Outcomes included body weight and body mass index (BMI) over time (z‐score growth curves), and treatment‐emergent adverse events (TEAEs). Previous/ongoing medical conditions that may affect body weight (gastrointestinal and metabolic/nutritional disorders); concomitant antiseizure medications (ASMs) were also evaluated.ResultsTwo hundred nine patients (mean [standard deviation] age 7.9 [4.6] years) were analyzed. Most (154 [73.7%]) had focal‐onset seizures. At study initiation, median (range) BRV dose was 1.0 (0.4–7.5) mg/kg/day. Overall, 189 (90.4%) patients had a previous or ongoing medical condition (gastrointestinal disorders: 43 [20.6%]; metabolism/nutritional disorders: 26 [12.4%]). Most patients followed z‐score curves for body weight and BMI during BRV treatment, although there were outliers in both directions. Incidences of appetite/weight‐change TEAEs were low. Twenty‐three (11.0%) patients had a TEAE of decreased appetite and 14 (6.7%) had a TEAE of weight decreased.SignificanceLong‐term adjunctive BRV was well tolerated in growing children with no indication of detrimental effects on body weight.Plain Language SummaryBrivaracetam is an antiseizure medication (ASM) used to treat seizures in people with epilepsy. Some ASMs can lead to changes in people's appetite and weight. Knowing the effect a drug has on appetite and weight is particularly important in children. We looked at 209 children with epilepsy taking brivaracetam and studied changes in their body weight and body mass index over time. The number of reported side effects related to appetite or weight change was low. There was no apparent long‐term effect on their body weight, even when taking their medical history and use of other ASMs into account.

show abstract

Reference growth curves of anthropometric markers in Brazilian children and adolescents aged 7–14 years from southern Brazil

Alves Junior,

da Silva,

Hinnig

et al. 2024

Nutrition Bulletin

View full text Add to dashboard Cite

Reference growth curves are viable tools for monitoring somatic growth. Therefore, the objective of this study was to develop reference growth curves for body mass, height, body mass index (BMI), waist circumference (WC) and waist‐to‐height ratio (WHtR) in Brazilian children and adolescents aged 7–14 years. The reference growth curves were constructed from a cross‐sectional panel study using data from four surveys conducted in 2002, 2007, 2012/2013 and 2018/2019, with 9675 children and adolescents aged 7–14 years, of both sexes from Florianopolis, Southern Brazil. Growth curves were constructed using the LMS method, based on anthropometric indicators and indices (body mass, height, BMI, WC and WHtR), measured according to standardised norms. There was an increase in body mass, height, BMI and WC values with increasing age in both sexes and percentiles (P5, P10, P25, P50, P75, P85 and P95). The girls presented higher values of body mass, BMI and WC in the analysed percentiles, compared to the boys. Regarding height, there was a higher value from 10 to 11 years old in girls and from 12 to 14 years old in boys. WHtR decreased with increasing age in both sexes and analysed percentiles. Region‐specific reference growth curves can enable the monitoring of somatic growth of particular paediatric populations, expanding discussions in different regions of the world.

show abstract

Reference growth curves to identify weight status (underweight, overweight or obesity) in children and adolescents: systematic review

Cited by 4 publications

References 91 publications

Molecular mechanisms of human overgrowth and use of omics in its diagnostics: chances and challenges

Molecular mechanisms of human overgrowth and use of omics in its diagnostics: chances and challenges

Treatment with brivaracetam has no apparent long‐term effects on body weight in pediatric patients with epilepsy

Reference growth curves of anthropometric markers in Brazilian children and adolescents aged 7–14 years from southern Brazil

Contact Info

Product

Resources

About